Koninklijke Philips NVRYLPF 73 EBITDA Margin % is 13.78% as of Mar. 2026, which is 2% below its 10-year median of 14.05. GuruFocus rates RYLPF with a GF Score™ of 73/100 and a GF Value™ of $25.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Koninklijke Philips NV ranks better than 65.93% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Koninklijke Philips NV EBITDA Margin % Related Terms
Koninklijke Philips NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Koninklijke Philips NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RYLPF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Koninklijke Philips NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Koninklijke Philips NV EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Koninklijke Philips NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Koninklijke Philips NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Koninklijke Philips NV (RYLPF) has a EBITDA Margin % of 13.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Koninklijke Philips NV and its competitors. This is near median its historical median of 14.05. Over the past decade, Koninklijke Philips NV's EBITDA Margin % has ranged from 0.65 to 16.49. According to the industry distribution chart, Koninklijke Philips NV ranks #278 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 34.1%.
Is Koninklijke Philips NV's EBITDA Margin % too high?
Koninklijke Philips NV's current EBITDA Margin % of 13.78% is near median its 10-year median of 14.05. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 16.49. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Koninklijke Philips NV's value of 13.78% is 84.3% above this industry median. Based on the distribution chart, Koninklijke Philips NV ranks #278 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Koninklijke Philips NV has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Koninklijke Philips NV ranks #278 out of 816 companies for EBITDA Margin %. This puts Koninklijke Philips NV in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Koninklijke Philips NV's value of 13.78% is 84.3% above this benchmark. Historically, Koninklijke Philips NV's own EBITDA Margin % has ranged from 0.65 to 16.49 over the past decade. While the company's 10-year median is 14.05 vs. the industry median of 7.48, Koninklijke Philips NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Koninklijke Philips NV's current EBITDA Margin % of 13.78% is 84.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Koninklijke Philips NV and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Koninklijke Philips NV's current EBITDA Margin % is 13.78%, which is near median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $25.13, compared to a current price of $26.19 — trading 4.2% above its estimated fair value. The current EBITDA Margin % is 13.78%, which is near median its 10-year median of 14.05 and 84.3% above the Medical Devices & Instruments industry median of 7.48. Koninklijke Philips NV's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current EBITDA Margin % is 13.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued.
The current stock price of $26.19 is trading 4.2% above its estimated GF Value™ of $25.13.
GuruFocus considers Koninklijke Philips NV to be Fairly Valued.
Key valuation signals for RYLPF:
EBITDA Margin %: 13.78% (near median its 10-year median of 14.05)
GF Value™: $25.13 vs. price of $26.19 (4.2% above fair value)
Industry Position: 84.3% above the Medical Devices & Instruments median (#278 of 816)
No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
73GF Score
Get the complete analysis for RYLPF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYLPF has been successfully added to your 
